Health expert: Europe should not put its dominant pharma innovation at risk

By |januar 29th, 2018|Adrian Towse, drug innovation, drug pricing, intellectual property rights, News, SPC manufacturing waiver|

The European Union should not create an environment more favourable to generics compared to the innovative pharmaceuticals, as it risks weakening Europe’s overall global strength in pharmaceuticals and in research, Professor Adrian Towse told EURACTIV.com in an interview.